Ireland
--:--IST
Recruiting Phase 2

Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema

NCT06710249 · tracked via the Priya Life Science Sweden tracker
Phase
Phase 2
Started
2024-01-27
Last updated
2025-01-27

Condition(s) studied

GlioblastomaCerebral MetastasesMeningioma

Investigational drug(s) / intervention(s)

Salovum/SPC flakes

Salovum/SPC flakes: Egg yolk powder and specially processed cereals

Study summary

The objective of this clinical trial is to explore the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, and SPC® flakes , hydrothermically processed oats, on cerebral edema with clinical symptoms in participants with brain tumors.

The primary questions the trial seeks to answer are:

* Can Salovum® and SPC® flakes have effect on clinical symptoms of tumor-induced cerebral edema?
* Can Salovum® and SPC® flakes induce regression of radiological edema in tumor-induced cerebral edema Additionally, the study will investigate the impact of Salovum® and SPC® flakes in steroid refractory, steroid naïve cerebral edema and type of barin tumor

Researchers will:

Evaluate edema change from baseline by MRI after 14 days Evaluate neurological and cognitive symptoms Register dose of steroid medications

Participants will:

* Ingest Salovum® 11g three times daily for 14 days, thereafter tapered during 14 days
* Ingest SPC® flakes 1g/kg daily from day 7

Eligibility

Sex
ALL
Min age
18 Years
Max age
79 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 18-79 years 2. Known or radiologically suspected primary or secondary brain tumor (suspected metastasis, meningioma, glioma, etc.) with surrounding edema causing clinical signs 3. GCS 14-15 4. WHO ECOG performance status 0-2 5. Planned or started cortisone treatment 6. Ability to provide informed consent Exclusion Criteria: 1. Egg yolk allergy 2. Midline shift \>5mm 3. GCS ≤13 4. Epilepsy as sole symptom from the cerebral edema

Primary outcome measure(s)

  • Change of neurological symptoms — 28 days
    To investigate whether Salovum® and SPC® flakes can change neurological symptoms in participants with tumor induced cerebral oedema as measured by the neurologic assessment in neurooncology (NANO) scale (range 0-23, 0 best-23 worst)

Trial sites (1)

FacilityCityRegionStatus
Department of Neurosurgery Lund Sweden Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06710249 on ClinicalTrials.gov ↗ ← All trials in Sweden